Desvenlafaxine: A therapeutic option for treatment of menopausal hot flashes

Maturitas

Volumn 66, Issue 1, 2010, Pages 1-2

  Archer, David F ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESVENLAFAXINE; GABAPENTIN; CYCLOHEXANOL DERIVATIVE; O-DESMETHYLVENLAFAXINE; SEROTONIN UPTAKE INHIBITOR;

CARDIOVASCULAR DISEASE; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERTENSION; MENOPAUSE; NAUSEA; NONHUMAN; PATIENT COUNSELING; UNSPECIFIED SIDE EFFECT; VOMITING; FEMALE; HOT FLASHES;

CYCLOHEXANOLS; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; SEROTONIN UPTAKE INHIBITORS;

EID: 77950863682     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.02.007     Document Type: Editorial

References (36)

1. Dennerstein L., Lehert P., Koochaki P.E., Graziottin A., Leiblum S., and Alexander J.L. A symptomatic approach to understanding women's health experiences: a cross-cultural comparison of women aged 20 to 70 years. Menopause (New York, NY) 14 4 (2007) 688-696
2. Green R., and Santoro N. Menopausal symptoms and ethnicity: the Study of Women's Health Across the Nation. Women's Health (London, England) 5 2 (2009) 127-133
3. Guthrie J.R., Dennerstein L., Taffe J.R., Lehert P., and Burger H.G. Hot flushes during the menopause transition: a longitudinal study in Australian-born women. Menopause (New York, NY) 12 4 (2005) 460-467
4. Maclennan A.H., Broadbent J.L., Lester S., and Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews (Online) 4 (2004) CD002978
5. Utian W.H. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health and Quality of Life Outcomes 3 (2005) 47
6. Hess R., Colvin A., Avis N.E., et al. The impact of hormone therapy on health-related quality of life: longitudinal results from the Study of Women's Health Across the Nation. Menopause (New York, NY) 15 3 (2008) 422-428
7. Spetz A.C., Palmefors L., Skobe R.S., et al. Testosterone correlated to symptoms of partial androgen deficiency in aging men (PADAM) in an elderly Swedish population. Menopause (New York, NY) 14 6 (2007) 999-1005
8. Freedman R.R. Pathophysiology and treatment of menopausal hot flashes. Seminars in Reproductive Medicine 23 2 (2005) 117-125
9. Freedman R.R. Core body temperature variation in symptomatic and asymptomatic postmenopausal women: brief report. Menopause (New York, NY) 9 6 (2002) 399-401
10. Freedman R.R. Physiology of hot flashes. The American Journal of Human Biology 13 4 (2001) 453-464
11. Albertazzi P. Non-estrogenic approaches for the treatment of climacteric symptoms. Climacteric 10 Suppl. 2 (2007) 115-120
12. Daley A.J., Stokes-Lampard H.J., and Macarthur C. Exercise to reduce vasomotor and other menopausal symptoms: a review. Maturitas 63 3 (2009) 176-180
13. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause (New York, NY) 2004;11(1):11-33.
14. Deecher D.C. Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms. Expert Opinion on Investigational Drugs 14 4 (2005) 435-448
15. Deecher D.C., and Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Archives of Women's Mental Health 10 6 (2007) 247-257
16. Karkanias G.B., Ansonoff M.A., and Etgen A.M. Estradiol regulation of alpha 1b-adrenoceptor mRNA in female rat hypothalamus-preoptic area. Journal of Neuroendocrinology 8 6 (1996) 449-455
17. Gundlah C., Pecins-Thompson M., Schutzer W.E., and Bethea C.L. Ovarian steroid effects on serotonin 1A, 2A and 2C receptor mRNA in macaque hypothalamus. Brain Research. Molecular Brain Research 63 2 (1999) 325-339
18. Freedman R.R., and Dinsay R. Clonidine raises the sweating threshold in symptomatic but not in asymptomatic postmenopausal women. Fertility and Sterility 74 1 (2000) 20-23
19. Freedman R.R. Hot flashes: behavioral treatments, mechanisms, and relation to sleep. The American Journal of Medicine 118 Suppl. 12B (2005) 124-130
20. Berendsen H.H. The role of serotonin in hot flushes. Maturitas 36 3 (2000) 155-164
21. Ikeda M., Egawa T., Yamauchi A., et al. Selective serotonin reuptake inhibitors fluvoxamine and paroxetine restore forced exercise-induced temperature dysregulation in ovariectomized mice. European Journal of Pharmacology 579 1-3 (2008) 439-444
22. Carroll D.G., and Kelley K.W. Use of antidepressants for management of hot flashes. Pharmacotherapy 29 11 (2009) 1357-1374
23. Pinkerton J.V., Stovall D.W., and Kightlinger R.S. Advances in the treatment of menopausal symptoms. Women's Health (London, England) 5 4 (2009) 361-384 [quiz 83-4]
24. Carroll D.G. Nonhormonal therapies for hot flashes in menopause. American family physician 73 3 (2006) 457-464
25. Brown J.N., and Wright B.R. Use of gabapentin in patients experiencing hot flashes. Pharmacotherapy 29 1 (2009) 74-81
26. Archer D.F., Dupont C.M., Constantine G.D., Pickar J.H., and Olivier S. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. American Journal of Obstetrics and Gynecology 200 3 (2009) 238.e1-238.e10
27. Archer D.F., Seidman L., Constantine G.D., Pickar J.H., and Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. American Journal of Obstetrics and Gynecology 200 2 (2009) 172.e1-172.e10
28. Speroff L., Gass M., Constantine G., and Olivier S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstetrics and Gynecology 111 1 (2008) 77-87
29. Deecher D.C., Beyer C.E., Johnston G., et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. The Journal of Pharmacology and Experimental Therapeutics 318 2 (2006) 657-665
30. Stearns V. Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms. Treatments in Endocrinology 5 2 (2006) 83-87
31. Thurston R.C., Bromberger J.T., Joffe H., et al. Beyond frequency: who is most bothered by vasomotor symptoms?. Menopause (New York, NY) 15 5 (2008) 841-847
32. Kamath J., and Handratta V. Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Review of Neurotherapeutics 8 12 (2008) 1787-1797
33. Joffe H., Soares C.N., Petrillo L.F., et al. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. The Journal of Clinical Psychiatry 68 6 (2007) 943-950
34. Sproule B.A., Hazra M., and Pollock B.G. Desvenlafaxine succinate for major depressive disorder. Drugs Today (Barc) 44 7 (2008) 475-487
35. Swenson J.R., Doucette S., and Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Canadian Journal of Psychiatry 51 14 (2006) 923-929
36. Sauer W.H., Berlin J.A., and Kimmel S.E. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 108 1 (2003) 32-36